healthcare-and-pharmaceuticals5.02 min read
"Eli Lilly Partners with Amazon Pharmacy for Zepbound Weight Loss Drug Delivery"
1 year ago•Source: CNBC
Healthcare And Pharmaceuticals News
The latest healthcare and pharmaceuticals stories, summarized by AI
Featured Healthcare And Pharmaceuticals Stories
View original source
2.015 min•1 year ago
Viking Therapeutics' Weight-Loss Drug Trial Results Double Stock
Viking Therapeutics, a San Diego-based company, has announced promising results for its new weight loss drug, a GLP-1 drug similar to Ozempic, with users achieving an average 14% weight loss from baseline numbers after 13 weeks of treatment. This news has caused a surge in Viking Therapeutics' stock value as investors seek a cheaper path into the weight loss drug market currently dominated by Novo Nordisk and Eli Lilly. Other pharmaceutical companies like Regeneron, Amgen, and Zealand Pharma are also developing weight loss drugs to capture some of the market share held by the two giants. Zealand Pharma's stock soared after announcing strong results in a clinical trial for a liver disease drug that is also being tested for weight loss.
More Top Stories
2
3
More Healthcare And Pharmaceuticals Stories
"J&J's $2 Billion Acquisition of Ambrx Biopharma Signals Major Advances in Cancer Treatment"
Originally Published 2 years ago — by Reuters
Johnson & Johnson and Merck kick off a major U.S. healthcare conference by announcing plans to acquire cancer therapy developers, with combined deals worth over $6 billion, signaling a strong start for M&A in 2024. J&J is set to buy Ambrx Biopharma for $2 billion to gain targeted cancer therapies, while Merck plans to acquire Harpoon Therapeutics for about $680 million to access early-stage immunotherapies for lung cancer and multiple myeloma. Additionally, medical device maker Boston Scientific is entering the market with a $3.7 billion deal for Axonics Inc, reflecting a return to business as usual in the pharmaceutical industry after the challenges of 2023.
Johnson & Johnson's $2 Billion Acquisition of Cancer Drug Developer Ambrx Biopharma
Originally Published 2 years ago — by CNBC
Johnson & Johnson has announced its $2 billion acquisition of Ambrx Biopharma, a company specializing in cancer treatment through antibody-drug conjugates (ADCs). This move reflects J&J's strategy to fill a revenue gap expected in 2025 and follows similar investments by other major pharmaceutical companies. The acquisition is expected to enhance J&J's oncology pipeline and provide opportunities for precision biologics in cancer treatment.
Johnson & Johnson's $2 Billion Acquisition of Ambrx Signals Major Move in Cancer Treatment
Originally Published 2 years ago — by Endpoints News
Johnson & Johnson has made a $2 billion cash deal to acquire Ambrx Biopharma, joining other major pharmaceutical companies in a spree of acquisitions focused on antibody-drug conjugates in the oncology sector. This move comes as the industry anticipates increased spending to bolster pipelines ahead of looming patent expirations at the end of the decade.